These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 35169778)

  • 1. From Genetics to Epigenetics: Top 4 Aspects for Improved SARS-CoV-2 Vaccine Designs as Paradigmatic Examples.
    Kanduc D
    Glob Med Genet; 2022 Mar; 9(1):14-17. PubMed ID: 35169778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targets and strategies for vaccine development against SARS-CoV-2.
    Malik JA; Mulla AH; Farooqi T; Pottoo FH; Anwar S; Rengasamy KRR
    Biomed Pharmacother; 2021 May; 137():111254. PubMed ID: 33550049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differences in IgG Antibody Responses following BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines.
    Montoya JG; Adams AE; Bonetti V; Deng S; Link NA; Pertsch S; Olson K; Li M; Dillon EC; Frosch DL
    Microbiol Spectr; 2021 Dec; 9(3):e0116221. PubMed ID: 34756093
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Long Road Toward COVID-19 Herd Immunity: Vaccine Platform Technologies and Mass Immunization Strategies.
    Frederiksen LSF; Zhang Y; Foged C; Thakur A
    Front Immunol; 2020; 11():1817. PubMed ID: 32793245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of Graves' Disease After SARS-CoV-2 mRNA Vaccination: A Case Report and Literature Review.
    Lui DTW; Lee KK; Lee CH; Lee ACH; Hung IFN; Tan KCB
    Front Public Health; 2021; 9():778964. PubMed ID: 34888290
    [No Abstract]   [Full Text] [Related]  

  • 6. Attitudes towards vaccines and intention to vaccinate against COVID-19: a cross-sectional analysis-implications for public health communications in Australia.
    Enticott J; Gill JS; Bacon SL; Lavoie KL; Epstein DS; Dawadi S; Teede HJ; Boyle J;
    BMJ Open; 2022 Jan; 12(1):e057127. PubMed ID: 34980631
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Vaccination against SARS-CoV-2 in patients with multiple sclerosis].
    Costa Frossard-França L; García-Domínguez JM; Moreno-Torres I; Fortún J; Villar LM; Meca-Lallana V
    Rev Neurol; 2021 Apr; 72(7):250-260. PubMed ID: 33764494
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-Dose Immunization With a Chimpanzee Adenovirus-Based Vaccine Induces Sustained and Protective Immunity Against SARS-CoV-2 Infection.
    Li M; Guo J; Lu S; Zhou R; Shi H; Shi X; Cheng L; Liang Q; Liu H; Wang P; Wang N; Wang Y; Fu L; Xing M; Wang R; Ju B; Liu L; Lau SY; Jia W; Tong X; Yuan L; Guo Y; Qi H; Zhang Q; Huang Z; Chen H; Zhang Z; Chen Z; Peng X; Zhou D; Zhang L
    Front Immunol; 2021; 12():697074. PubMed ID: 34262569
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccine hesitancy among people with multiple sclerosis.
    Yap SM; Al Hinai M; Gaughan M; Callanan I; Kearney H; Tubridy N; McGuigan C
    Mult Scler Relat Disord; 2021 Nov; 56():103236. PubMed ID: 34507240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DNA vaccine protection against SARS-CoV-2 in rhesus macaques.
    Yu J; Tostanoski LH; Peter L; Mercado NB; McMahan K; Mahrokhian SH; Nkolola JP; Liu J; Li Z; Chandrashekar A; Martinez DR; Loos C; Atyeo C; Fischinger S; Burke JS; Slein MD; Chen Y; Zuiani A; Lelis FJN; Travers M; Habibi S; Pessaint L; Van Ry A; Blade K; Brown R; Cook A; Finneyfrock B; Dodson A; Teow E; Velasco J; Zahn R; Wegmann F; Bondzie EA; Dagotto G; Gebre MS; He X; Jacob-Dolan C; Kirilova M; Kordana N; Lin Z; Maxfield LF; Nampanya F; Nityanandam R; Ventura JD; Wan H; Cai Y; Chen B; Schmidt AG; Wesemann DR; Baric RS; Alter G; Andersen H; Lewis MG; Barouch DH
    Science; 2020 Aug; 369(6505):806-811. PubMed ID: 32434945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
    Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
    Front Immunol; 2021; 12():802858. PubMed ID: 35003131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of High Levels of Specific Humoral and Cellular Responses to SARS-CoV-2 After the Administration of Covid-19 mRNA Vaccines Requires Several Days.
    Gil-Manso S; Carbonell D; López-Fernández L; Miguens I; Alonso R; Buño I; Muñoz P; Ochando J; Pion M; Correa-Rocha R
    Front Immunol; 2021; 12():726960. PubMed ID: 34671348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine.
    Melo-González F; Soto JA; González LA; Fernández J; Duarte LF; Schultz BM; Gálvez NMS; Pacheco GA; Ríos M; Vázquez Y; Rivera-Pérez D; Moreno-Tapia D; Iturriaga C; Vallejos OP; Berríos-Rojas RV; Hoppe-Elsholz G; Urzúa M; Bruneau N; Fasce RA; Mora J; Grifoni A; Sette A; Weiskopf D; Zeng G; Meng W; González-Aramundiz JV; González PA; Abarca K; Ramírez E; Kalergis AM; Bueno SM
    Front Immunol; 2021; 12():747830. PubMed ID: 34858404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of Effectiveness of 1 Dose of BNT162b2 Vaccine for SARS-CoV-2 Infection 13 to 24 Days After Immunization.
    Chodick G; Tene L; Patalon T; Gazit S; Ben Tov A; Cohen D; Muhsen K
    JAMA Netw Open; 2021 Jun; 4(6):e2115985. PubMed ID: 34097044
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity.
    Chaudhary JK; Yadav R; Chaudhary PK; Maurya A; Kant N; Rugaie OA; Haokip HR; Yadav D; Roshan R; Prasad R; Chatrath A; Singh D; Jain N; Dhamija P
    Cells; 2021 Oct; 10(11):. PubMed ID: 34831172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Consensus summary report for CEPI/BC March 12-13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines.
    Lambert PH; Ambrosino DM; Andersen SR; Baric RS; Black SB; Chen RT; Dekker CL; Didierlaurent AM; Graham BS; Martin SD; Molrine DC; Perlman S; Picard-Fraser PA; Pollard AJ; Qin C; Subbarao K; Cramer JP
    Vaccine; 2020 Jun; 38(31):4783-4791. PubMed ID: 32507409
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A human cell-based SARS-CoV-2 vaccine elicits potent neutralizing antibody responses and protects mice from SARS-CoV-2 challenge.
    He X; Ding L; Cao K; Peng H; Gu C; Li Y; Li D; Dong L; Hong X; Wang X; Fu M; Qiu C; Zhu C; Zhang Z; Song S; Wang C; Jiang Z; Xie Y; Qi Z; Zhao C; Zhao P; Zhang X; Xu J
    Emerg Microbes Infect; 2021 Dec; 10(1):1555-1573. PubMed ID: 34304724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Humoral immune responses during SARS-CoV-2 mRNA vaccine administration in seropositive and seronegative individuals.
    Fraley E; LeMaster C; Geanes E; Banerjee D; Khanal S; Grundberg E; Selvarangan R; Bradley T
    BMC Med; 2021 Jul; 19(1):169. PubMed ID: 34304742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peritoneal Administration of a Subunit Vaccine Encapsulated in a Nanodelivery System Not Only Augments Systemic Responses against SARS-CoV-2 but Also Stimulates Responses in the Respiratory Tract.
    Jearanaiwitayakul T; Apichirapokey S; Chawengkirttikul R; Limthongkul J; Seesen M; Jakaew P; Trisiriwanich S; Sapsutthipas S; Sunintaboon P; Ubol S
    Viruses; 2021 Nov; 13(11):. PubMed ID: 34835008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical characteristics of healthcare workers with SARS-CoV-2 infection after vaccination with BNT162b2 vaccine.
    Lombardi A; Renisi G; Consonni D; Oggioni M; Bono P; Uceda Renteria S; Piatti A; Pesatori AC; Castaldi S; Muscatello A; Riboldi L; Ceriotti F; Gori A; Bandera A
    BMC Infect Dis; 2022 Jan; 22(1):97. PubMed ID: 35090388
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.